These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37796539)

  • 1. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides.
    Morgan KA; Rudd SE; Noor A; Donnelly PS
    Chem Rev; 2023 Oct; 123(20):12004-12035. PubMed ID: 37796539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
    Van Laere C; Koole M; Deroose CM; de Voorde MV; Baete K; Cocolios TE; Duchemin C; Ooms M; Cleeren F
    Theranostics; 2024; 14(4):1720-1743. PubMed ID: 38389843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostics of Metastatic Prostate Cancer Applying
    Mirzaei S; Mohammed F; Zandieh S
    Curr Radiopharm; 2021; 14(4):354-358. PubMed ID: 32900357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging value of 64Cu for molecular imaging and therapy.
    Bolzati C; Duatti A
    Q J Nucl Med Mol Imaging; 2020 Dec; 64(4):329-337. PubMed ID: 33026210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutron-activated theranostic radionuclides for nuclear medicine.
    Tan HY; Yeong CH; Wong YH; McKenzie M; Kasbollah A; Md Shah MN; Perkins AC
    Nucl Med Biol; 2020; 90-91():55-68. PubMed ID: 33039974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.
    Zhang J; Singh A; Kulkarni HR; Schuchardt C; Müller D; Wester HJ; Maina T; Rösch F; van der Meulen NP; Müller C; Mäcke H; Baum RP
    Semin Nucl Med; 2019 Sep; 49(5):422-437. PubMed ID: 31470935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
    Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
    Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings.
    Follacchio GA; De Feo MS; De Vincentis G; Monteleone F; Liberatore M
    Curr Radiopharm; 2018; 11(1):22-33. PubMed ID: 29231149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
    Parus JL; Mikolajczak R
    Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
    Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
    Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immunotargeting using innovative radionuclides.
    Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Mathieu C; Guérard F; Frampas E; Carlier T; Chouin N; Haddad F; Chatal JF; Faivre-Chauvet A; Chérel M; Barbet J
    Int J Mol Sci; 2015 Feb; 16(2):3932-54. PubMed ID: 25679452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oncological theranostics in nuclear medicine].
    Laschinsky C; Herrmann K; Fendler W; Nader M; Lahner H; Hadaschik B; Sandach P
    Radiologie (Heidelb); 2022 Oct; 62(10):875-884. PubMed ID: 36112174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M
    Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper radiopharmaceuticals for theranostic applications.
    Ahmedova A; Todorov B; Burdzhiev N; Goze C
    Eur J Med Chem; 2018 Sep; 157():1406-1425. PubMed ID: 30282317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper chelation chemistry and its role in copper radiopharmaceuticals.
    Wadas TJ; Wong EH; Weisman GR; Anderson CJ
    Curr Pharm Des; 2007; 13(1):3-16. PubMed ID: 17266585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
    Ruigrok EAM; Tamborino G; de Blois E; Roobol SJ; Verkaik N; De Saint-Hubert M; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3627-3638. PubMed ID: 35556158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical efficacy of hK2 targeted [
    Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
    Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.